From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment, health-care analyst David Williamson discusses Johnson & Johnson's massive $2.2 billion settlement with the Department of Justice, amid allegations that the company gave its sales representatives incentive to market the company's antipsychotic drug Risperdal for off-label sales. David looks at just how common these types of allegations and settlements are, and says that despite the worrying headlines, investors shouldn't be concerned.
Check out these dividend winners
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notability of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
The article Why Johnson & Johnson Is Paying the Department of Justice Billions originally appeared on Fool.com.Alison Southwick has no position in any stocks mentioned. David Williamson owns shares of Pfizer, Abbott Labs, And Johnson & Johnson. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.